These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Characterization of Miller AA; Moussa SH; McLeod SM Antimicrob Agents Chemother; 2024 May; 68(5):e0169823. PubMed ID: 38567976 [No Abstract] [Full Text] [Related]
6. In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance. Findlay J; Poirel L; Bouvier M; Nordmann P J Glob Antimicrob Resist; 2022 Sep; 30():445-450. PubMed ID: 35618210 [TBL] [Abstract][Full Text] [Related]
7. Sulbactam-durlobactam susceptibility test method development and quality control ranges for MIC and disk diffusion tests. McLeod SM; Carter NM; Huband MD; Traczewski MM; Bradford PA; Miller AA J Clin Microbiol; 2024 Jan; 62(1):e0122823. PubMed ID: 38095417 [TBL] [Abstract][Full Text] [Related]
8. The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex. O'Donnell JP; Bhavnani SM Clin Infect Dis; 2023 May; 76(Suppl 2):S202-S209. PubMed ID: 37125469 [TBL] [Abstract][Full Text] [Related]
9. Sulbactam-Durlobactam, A Novel Drug for the Treatment of Multidrug Resistant Velmurugan H; Venkatesan S; Meles HN; Neelambaram K; Thangaraju P Infect Disord Drug Targets; 2024; 24(6):e220124225835. PubMed ID: 38258766 [TBL] [Abstract][Full Text] [Related]
10. Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species. Papp-Wallace KM; McLeod SM; Miller AA Clin Infect Dis; 2023 May; 76(Suppl 2):S194-S201. PubMed ID: 37125470 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Kaye KS; Shorr AF; Wunderink RG; Du B; Poirier GE; Rana K; Miller A; Lewis D; O'Donnell J; Chen L; Reinhart H; Srinivasan S; Isaacs R; Altarac D Lancet Infect Dis; 2023 Sep; 23(9):1072-1084. PubMed ID: 37182534 [TBL] [Abstract][Full Text] [Related]
13. Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii. McLeod SM; Shapiro AB; Moussa SH; Johnstone M; McLaughlin RE; de Jonge BLM; Miller AA Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133555 [TBL] [Abstract][Full Text] [Related]
15. In vitro antibacterial activity of sulbactam-durlobactam in combination with other antimicrobial agents against Acinetobacter baumannii-calcoaceticus complex. McLeod SM; Carter NM; Bradford PA; Miller AA Diagn Microbiol Infect Dis; 2024 Jul; 109(3):116344. PubMed ID: 38735147 [TBL] [Abstract][Full Text] [Related]
16. Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant August B; Matlob A; Kale-Pradhan PB Ann Pharmacother; 2024 Jul; 58(7):735-741. PubMed ID: 37817550 [TBL] [Abstract][Full Text] [Related]
18. Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Petropoulou D; Siopi M; Vourli S; Pournaras S Front Cell Infect Microbiol; 2021; 11():814530. PubMed ID: 35127562 [TBL] [Abstract][Full Text] [Related]